Cell Cycle and Survival Signaling Proteins

The term 'Cell Cycle and Survival Signaling Proteins' refers to a heterogeneous group of molecules rather than a single therapeutic target. This category encompasses essential regulatory proteins such as Cyclin-Dependent Kinases (CDKs), cyclins, the BCL-2 family of apoptosis regulators, and transducers within the PI3K/AKT/mTOR and MAPK/ERK signaling pathways (Source: NIH/NCBI, Bookshelf NBK9876). These proteins govern the orderly progression of the cell through its division cycle and integrate external signals to determine whether a cell survives or undergoes apoptosis. In various diseases, particularly cancer, these proteins are frequently mutated or overexpressed, leading to uncontrolled cellular proliferation and evasion of programmed cell death (Source: StatPearls, 2023). Therapeutic strategies often involve the use of small molecule inhibitors designed to restore cell cycle checkpoints or inhibit survival signals that confer resistance to treatment. Because these proteins play fundamental roles in normal tissue homeostasis, pharmacological modulation often necessitates balancing efficacy against systemic toxicities like bone marrow suppression and metabolic disturbances. This entry is flagged as 'incorrect' for a specific target profile because it represents a broad functional classification or pathway group rather than a distinct, individual molecular entity.

Other names

Cell cycle regulatorsCell survival signaling pathway componentsApoptosis and proliferation proteinsCell cycle and survival pathway

Drugs targeting these proteins typically function by inhibiting specific nodes within survival pathways or cell cycle checkpoints, such as blocking Cyclin-Dependent Kinases (CDK4/6) to induce G1 phase arrest, or inhibiting anti-apoptotic proteins like BCL-2 to trigger programmed cell death in malignant cells (Source: Nature Reviews Cancer, 2021; PubMed PMID: 33436825).